Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCAA vs Rifaximin for HE Prophylaxis (HERB)
NCT06538077Phase 4Recruiting
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Branchamin in hepatic encephalopathy (HE), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Number of breakthrough event of overt hepatic encephalopathy at 24 weeks. Started Feb 2025; status: recruiting.
02
Drugs
Branchamin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT06538077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538077.